To access this element change to forms mode OFF
Grant Award View - GA207606
Pursuing IRF4 as a therapeutic opportunity for lymphoid malignancies
GA ID:
GA207606
Agency:
National Health and Medical Research Council (NHMRC)
Approval Date:
3-Nov-2021
Publish Date:
4-Jan-2022
Category:
Medical Research
Grant Term:
1-Jan-2022 to 31-Dec-2025
Value (AUD):
$1,434,231.80
(GST inclusive where applicable)
One-off/Ad hoc:
No
Aggregate Grant Award:
No
PBS Program Name:
NHMRC 20/21 1.1 Health and Medical Research
Grant Program:
Ideas Grants
Grant Activity:
Pursuing IRF4 as a therapeutic opportunity for lymphoid malignancies
Purpose:
The molecule IRF4 is essential to the function of the immune system. In this application we investigate mouse models with mutations in IRF4 that are identical to those found in patients with cancers of the immune system. We will investigate how these mutations affect binding of IRF4 to the DNA and how changes in the IRF4-DNA binding domain lead to formation of tumours and how this interaction can be targeted therapeutically.
GO ID:
GO Title:
2021 Ideas Grants
Internal Reference ID:
2021/GNT2012498
Selection Process:
Targeted or Restricted Competitive
Confidentiality - Contract:
Yes
Confidentiality Reason(s) - Contract:
Privacy Act 1988
Intellectual property
Intellectual property
Confidentiality - Outputs:
Yes
Confidentiality Reason(s) - Outputs:
Intellectual property
Grant Recipient Details
Recipient Name:
Australian National University
Recipient ABN:
52 234 063 906
Grant Recipient Location
Suburb:
Canberra City
Town/City:
Canberra City
Postcode:
2601
State/Territory:
ACT
Country:
AUSTRALIA
Grant Delivery Location
State/Territory:
ACT
Postcode:
Country:
AUSTRALIA